Abstract
2 population level, primarily due to technical challenges. We surveyed common and rare CNVs in 26 the exome sequences of 50,726 adult DiscovEHR study participants with linked electronic 27 health records (EHRs). We evaluated the diagnostic yield and clinical expressivity of known 28 pathogenic CNVs, and performed tests of association with EHR-derived serum lipids, thereby 29 evaluating the relationship between CNVs and complex traits and phenotypes in an unbiased, 30 real-world clinical context. We identified CNVs from megabase to exon-level resolution, 31 demonstrating reliable, high-throughput detection of clinically relevant exonic CNVs. In doing so, 32
we created a catalog of high-confidence common and rare CNVs and refined population 33 frequency estimates of known and novel gene-disrupting CNVs. Our survey among an 34 unselected clinical population provides further evidence that neuropathy-associated duplications 35 and deletions in 17p12 have similar population prevalence but are clinically under-diagnosed. 36
Similarly, adults who harbor 22q11.2 deletions frequently had EHR documentation of 37 neurodevelopmental/neuropsychiatric disorders and congenital anomalies, but not a formal 38 genetic diagnosis (i.e., deletion). In an exome-wide association study of lipid levels, we 39 identified a novel five-exon duplication within LDLR segregating in a large kindred with features 40 6 documented recurrent CNVs; our observed prevalence of 1 in 3,946 in the DiscovEHR cohort is 121 in line with previous estimates of 1 in 4,000 live births 12 . Of the 12 participants with a 22q11.2 122 deletion, 10 (83%) had ICD-9 codes consistent with the 22q11.2 deletion syndrome phenotype, 123 including 8 (67%) with a diverse set of neurodevelopmental/neuropsychiatric disorders (NDD) 124 and 6 (50%) with congenital anomalies, with 5/12 (42%) participants having both NDD and 125 congenital anomaly phenotypes reported (Supplementary Methods). However, only one 126 patient-participant (age 50 years old) with a 22q11.2 deletion had a specific genetic diagnosis of 127 velocardiofacial syndrome (ICD 758.32) documented in their EHR, suggesting that most 128 individuals are likely unaware of the genetic etiology of their clinical phenotypes. 129
We also found 25 patient-participants with 17p12 duplications that include the PMP22 130 gene; 21 having duplications spanning the common recurrent CNV locus associated with the 131 most common form of peripheral neuropathy, Charcot-Marie-Tooth disease type 1A (CMT1A; 132 MIM #118220) 13 , three with atypical duplications in two families, and one with breakpoints that 133 could not be reliably estimated (Supplementary Fig. S12 ). Fourteen out of 21 of the patient-134 participants with a common recurrent duplication and 2/3 with an atypical duplication (a parent-135 child duo) had a clinical diagnosis of CMT1A. Seven out of 21 individuals with a recurrent 136 duplication had non-specific diagnoses consistent with CMT1A recorded in their EHR 137 (Supplementary Methods). Three patient-participants had neuropathy phenotypes attributed to 138 type-2 diabetes, suggesting a possible misdiagnosis of the primary hereditary neuropathy. 139
Similarly, we identified and validated 26 patient-participants with the reciprocal 17p12 deletion 140 associated with Hereditary Neuropathy with liability to Pressure Palsies (HNPP; MIM 141 #162500) 13 , all of which spanned the common recurrent CNV region. However, only 1/26 142 patient-participants had a clinical diagnosis of HNPP in their EHR and 6 had consistent, but 143 non-specific diagnoses. Our observed population frequencies for the recurrent CMT-associated 144 duplication (1/2,255 total, 1/2,785 de novo; Supplementary Methods) and the related HNPP-145 associated deletion (1/1,821 total, 1/2,255 de novo) are roughly equal, but their EHR-based7 diagnostic rates are vastly different, suggesting that the deletion is largely clinically under-147 diagnosed. Forty-nine patient-participants with 17p12 CNVs and five non-carrier relatives were 148 validated with qPCR, demonstrating accurate identification of this clinically relevant CNV from 149 the exome data ( Supplementary Fig. S12 & Methods) We next tested the ability to identify novel disease susceptibility loci through the intersection of 159 exome CNVs and EHR-derived phenotypes. We performed an exome-wide association study of 160 our CNV loci with fasting serum lipid levels (Methods), which are heritable risk factors for 161 ischemic cardiovascular disease, in a subset of 39,087 individuals with available lipid data. At a 162
Bonferroni-corrected significance threshold of p<1.2x10 -5 , three CNV loci significantly 163 associated with lipid levels ( repeats within introns 12 and 17 using whole-genome sequencing, confirming a tandem 170 insertion site predicted to occur in-frame ( Fig. 2A) . The duplication was validated in all carriers 171 by Sanger sequencing (Supplementary Fig. S6 ). CNVs have previously been reported in 172 8 LDLR 14 ; however, this duplication appears to be novel. In overexpression experiments in 173 HEK293 cells (Supplementary Methods), LDLR containing the exon 13-17 tandem duplication 174 (Dup13-17) produced a larger protein product than the wild-type (WT) receptor that accumulates 175 in the endoplasmic reticulum. As a result, the mutant receptor is not expressed on the cellular 176 surface and has no LDL uptake activity. Thus, the duplication behaves similarly to the known 177 FH-causing p.G549D point mutation, classified as a transport-inhibiting (class-2) mutation (Figs. 178 Taken We also identified a common deletion encompassing the last 6/7 exons of the leukocyte 196 
2B-E & S13).
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218
Our study demonstrates the utility of exome sequencing data for analyzing common and 219 rare CNVs in the emerging paradigm of precision medicine using EHR-derived health 220 information. We show robust detection of small exonic CNVs well below the size threshold of 221 array-based technologies (Supplementary Methods), providing further evidence that the 222 density of markers on genotyping arrays is insufficient for characterizing the full CNV spectrum 223 in humans and necessitates higher resolution methods (Supplementary Fig. S4) . 224
Our catalog of exonic CNVs represents a substantial source of genomic variation in the 225
DiscovEHR study population and exemplifies the clinical value of CNVs. We survey the clinical 226 expressivity of known pathogenic CNVs, and via exome-wide associations with serum lipid 227 traits, discover a novel duplication in LDLR causing familial hypercholesterolemia (FH) Supplementary Methods), LDLR may be particularly prone to genomic rearrangements 21 . 238
These data highlight the potential for high-throughput CNV screening to improve diagnostic 239 rates for FH and inform patient treatment. 240
With the growing prevalence of whole-exome and whole-genome sequencing, the 241 substantial body of literature implicating CNVs in both rare and common disease, and the 242 magnitude of copy-number variation we observe in the exome, the inclusion of methods to 243 identify CNVs and other structural variants within standard sequence-based informatics 244 pipelines is long overdue. In addition, the ability to identify rare homozygous deletions (e.g. 245 2q13) in large cohort studies, like DiscovEHR, will contribute to human gene knockout catalogs 246 and the identification of autosomal recessive conditions. As we find that over 90% of distinct 247
CNVs are present in less than 1/5,000 individuals; large sample sizes or targeted recruitment of 248 additional family members are essential to establish phenotypic associations. Furthermore, 249 detection of exonic and larger clinically relevant CNVs from exome sequence data will 250 streamline genetic testing so that both sequence and copy number variants can be called from 251 one test methodology. The ability to obtain a more comprehensive view of human genetic 252 variation, both per individual and across populations, will facilitate the advent of precision 253 medicine. 254
255
METHODS
256
Study population 257
The human genetics studies were conducted as part of the DiscovEHR study of the Regeneron 258 CNV calling and quality control 294 CLAMMS 7 was applied to the exomes of all samples in parallel within a distributed compute 295 environment. CLAMMS calls CNVs from each sample's source BAM file using 1) base-level 296 depth-of-coverage calculations from aligned reads having mapping quality >= 30, and 2) seven 297 sequencing quality control (QC) metrics computed using Picard 298 (http://broadinstitute.github.io/picard/). Depth-of-coverage profiles are generated for exon 299 13 "windows" representing either the entire exon or a 500-1000 base pair contiguous segment of 300 an exon for long exons. Exon window coverage distributions are normalized independently for 301 every sample, adjusting for GC content and overall sequencing depth. CLAMMS detects CNVs 302 by comparing a sample's normalized coverage profile to a reference panel of 100 samples 303 matched with respect to QC metrics via a k-nearest neighbors search, where expected 304 coverage distributions are modelled with exon-window specific mixture models linked together 305 with a genomic distance-aware Hidden Markov Model (HMM). 306
Extensive quality control procedures were applied to the call set with the goal of 307 producing a set of CNV loci exhibiting high specificity (see Supplementary Methods). Briefly, 308 the sample set was filtered of "outlier" samples having inflated CNV rates (>28 CNVs, 2x 309 median) resulting in a high-confidence call set containing 47,349 samples (93%). CNVs in the 310 remaining samples were annotated with: 1) two model-based metrics from CLAMMS (Q non_dip 311 and Q exact , representing confidence measures that the region is non-diploid and consistent with 312 the exact called copy number, respectively), 2) allele balance and zygosity of SNVs within called 313 CNV regions, 3) the frequency of overlapping CNVs among outlier samples, and 4) the quality 314 and zygosity measures for all non-outlier carriers of the locus (representing cohort-wide locus 315 performance). Filtering criteria based on these annotations were trained with respect to the 316 cohort-wide transmission rate of rare heterozygous CNVs among parent-child duos from 317 genetically reconstructed pedigrees generated with PRIMUS 27 . The training set was targeted to 318 47.5% transmission, achieving 47.36% transmission in the training set, 46.02% in the test set, 319 and 46.59% combined. This includes several small (1-3 exon) CNVs (~29% of loci) transmitted 320 at 42.17%, with single-exon CNVs (~8% of loci) being transmitted at 38.96% (Supplementary  321   Table S1 ). 322
CNV validation data 323
In a prior study 7 , we validated select common and rare CNV loci identified by CLAMMS using 324
TaqMan qPCR and demonstrated higher performance and resolution than alternative exome 325 14 CNV callers as well as CNV detection from SNP arrays. In the present study, we have 326 expanded our validation set to include additional TaqMan qPCR validation on a representative 327 set of 100 high-confidence CNV loci identified in 259 parent-child duos, with a focus on small 328 CNVs (1-3 exon; 86/100 loci) having at least one duo in which a non-transmission is predicted 329 from CLAMMS (i.e. present in the parent, absent in the child). This provided an unbiased 330 method to test the sensitivity and specificity of CLAMMS at high-confidence small CNV loci, 331 particularly with respect to interpretation of the cohort-wide transmission rate estimates (42.17% 332 for 1-3 exon CNVs, 38.96% for single-exon CNVs; Supplementary Table S1 ). Among the small 333 CNV loci, we observed 10.5% of non-transmission calls did not qPCR validate, corresponding to 334 a 2.2% FPR, 8% FNR, and a total error rate of 5.3% (1-accuracy). Among single-exon CNVs, 335 we observed a 3.5% FPR, 9.2% FNR, and a total error rate of 6.6% (Supplementary Table  336 
S3). 337
In addition to TaqMan qPCR validations, a large subset of samples (N=34,246) were 338 processed with Illumina HumanOmniExpressExome-8v1-2 genotyping arrays in twelve batches 339 and subsequently tested with PennCNV 28 . PennCNV calls were quality controlled using a 95 th 340 percentile cutoff applied to each batch for samples having extreme Log-R Ratio standard 341 deviation (LRR_SD) and B Allele Frequency (BAF) drift. Calls at neighboring loci were 342 considered for merging using the clean_cnv module with the --bp combine_seg flag. We tested 343 the transmission rate of PennCNV calls from samples in identified parent-child duo relationships 344 having fewer than 50 CNVs (N=21,792), as excessive numbers of CNVs often indicate low 345 sample quality, high rates of de novo mutation, or somatic copy number variation that would 346 confound transmission rate calculations. Consistent with our previous observations 7 , we found 347 that PennCNV calls were only reliable (i.e. produced transmission rates close to 50%) at size 348 thresholds approaching >100 Kb or larger (Supplementary Figure S4) . 349 C and triglycerides were log 10 transformed, and medication-adjusted LDL-C and total cholesterol 361 values were not transformed. We then calculated trait residuals after adjustment for age, age 2 , 362 sex, and the first ten principal components of ancestry, and rank-inverse-normal transformed 363 these residuals prior to exome-wide association analysis (Supplementary Methods) 
Statistical Analysis
